Patents Examined by Richard G Hutson
  • Modified type A DNA polymerases
    Patent number: 10961555
    Abstract: The present invention provides improved DNA polymerases, in particular, type A DNA polymerases, that may be better suited for applications in recombinant DNA technologies. Among other things, the present invention provides modified DNA polymerases derived from directed evolution experiments designed to select mutations that confer advantageous phenotypes under conditions used in industrial or research applications.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: March 30, 2021
    Assignee: Kapa Biosystems, Inc.
    Inventors: William Bourn, Maryke Appel, Gavin Rush, John Foskett, Paul J. McEwan
  • Methods, systems, and reagents for direct RNA sequencing
    Patent number: 10954496
    Abstract: Provided are compositions comprising recombinant polymerases that include amino acid substitutions, insertions, deletions, and/or exogenous features that confer modified properties upon the polymerase for sequencing RNA or RNA/DNA templates. Polymerases that topologically encircle the template nucleic acid are provided. Also provided are methods of using such polymerases to make a DNA or to sequence a template comprising RNA.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: March 23, 2021
    Assignee: Pacific Biosciences of California, Inc.
    Inventors: Satwik Kamtekar, Jeremiah Hanes
  • Methods for processing nucleic acid samples
    Patent number: 10954558
    Abstract: The present disclosure provides methods and systems for amplifying and analyzing nucleic acid samples. The present disclosure provides methods for preparing cDNA and/or DNA molecules and cDNA and/or DNA libraries using modified reverse transcriptases.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: March 23, 2021
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Arkadiusz Bibillo, Pranav Patel
  • Nucleic acid modifying enzymes
    Patent number: 10954495
    Abstract: This invention provides for an improved generation of novel nucleic acid modifying enzymes. The improvement is the fusion of a sequence-non-specific nucleic-acid-binding domain to the enzyme in a manner that enhances the ability of the enzyme to bind and catalytically modify the nucleic acid.
    Type: Grant
    Filed: August 13, 2018
    Date of Patent: March 23, 2021
    Assignee: Bio-Rad Laboratories, Inc.
    Inventor: Yan Wang
  • Methods for processing nucleic acid samples
    Patent number: 10954557
    Abstract: The present disclosure provides methods and systems for amplifying and analyzing nucleic acid samples. The present disclosure provides methods for preparing cDNA and/or DNA molecules and cDNA and/or DNA libraries using modified reverse transcriptases.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: March 23, 2021
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Arkadiusz Bibillo, Pranav Patel
  • Materials and methods utilizing biotin producing mutant hosts for the production of 7-carbon chemicals
    Patent number: 10947570
    Abstract: Disclosed are methods for regulating biosynthesis of at least one of pimelic acid, 7-aminoheptanoic acid, 7-hydroxyheptanoic acid, heptamethylenediamine, 7-aminoheptanoland 1,7-heptanediol (C7 building blocks) using a pathway having a pimeloyl-ACP intermediate, the method including the step of downregulating the activity of BioF. Also disclosed are recombinant hosts by fermentation in which the above methods are performed. Further disclosed are recombinant hosts for producing pimeloyl-ACP, the recombinant host including a deletion of a bioF gene.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: March 16, 2021
    Assignee: INV Nylon Chemicals Americas, LLC
    Inventors: Alexander Brett Foster, Stephen Thomas Cartman, Jonathan Kennedy
  • Amadoriase having improved specific activity
    Patent number: 10934530
    Abstract: This invention provides an amadoriase having improved specific activity on a glycated substrate, compared with conventional amadoriase. Provided is an amadoriase comprising a substitution of the amino acid at the position corresponding to position 64 of the amino acid sequence as shown in SEQ ID NO: 1 with an amino acid selected from the group consisting of glycine, serine, methionine, leucine, threonine, valine, and isoleucine, a method for measurement of HbA1c, and a reagent kit for measurement of HbA1c using such amadoriase. Such method and kit for measurement enable rapid, simple, and accurate quantification of HbA1c.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: March 2, 2021
    Assignee: Kikkoman Corporation
    Inventors: Atsushi Ichiyanagi, Airi Komatsuzaki
  • Detergent composition comprising a DNase
    Patent number: 10934535
    Abstract: The present invention relates to new polypeptides, nucleotides encoding the polypeptide, as well as methods of producing the polypeptides. The present invention also relates to detergent composition comprising polypeptides, a laundering method and the use of polypeptides.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: March 2, 2021
    Assignee: NOVOZYMES A/S
    Inventors: Klaus Gori, Henrik Marcus Geertz-Hansen, Jesper Salomon, Thomas Holberg Blicher, Mary Ann Stringer, Nikolaj Spodsberg, Tianqi Sun, Morten Gjermansen
  • Variants of TACE pro-domain as TNF-A inhibitor and their medical use
    Patent number: 10933122
    Abstract: A method of treating an inflammatory disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a pro-domain of TNF-alpha converting enzyme (TACE), said polypeptide being devoid of a catalytic domain of said TACE, said polypeptide comprising a modification at a site selected from the group consisting of R58, R56 and K57 which renders said polypeptide resistant to furin degradation said polypeptide being capable of downregulating an activity of TACE, thereby treating the inflammatory disease.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: March 2, 2021
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Irit Sagi, Eitan Wong, Ran Afik
  • Evolution of proteases
    Patent number: 10920208
    Abstract: Some aspects of this disclosure provide methods for phage-assisted continuous evolution (PACE) of proteases. Some aspects of this invention provide methods for evaluating and selecting protease inhibitors based on the likelihood of the emergence of resistant proteases as determined by the protease PACE methods provided herein. Some aspects of this disclosure provide strategies, methods, and reagents for protease PACE, including fusion proteins for translating a desired protease activity into a selective advantage for phage particles encoding a protease exhibiting such an activity and improved mutagenesis-promoting expression constructs. Evolved proteases that recognize target cleavage sites which differ from their canonical cleavage site are also provided herein.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: February 16, 2021
    Assignee: President and Fellows of Harvard College
    Inventors: David R. Liu, Bryan Dickinson, Michael S. Packer, Ahmed Hussein Badran
  • Soluble bacterial and fungal proteins and methods and uses thereof in inhibiting and dispersing biofilm
    Patent number: 10905749
    Abstract: The present disclosure relates to methods of treating or preventing a biofilm-related infection and methods of preventing and treating biofilm formation on indwelling medical devices, implants, and non-medical surfaces comprising administering at least one soluble microbial protein that is encoded by an exopolysaccharide biosynthetic operon or functional gene cluster, wherein the protein comprises a glycosyl hydrolase domain. The present disclosure further provides particular soluble glycosyl hydrolases and compositions thereof.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: February 2, 2021
    Assignees: The Hospital for Sick Children, The Royal Institution for the Advancement of Learning/McGill University
    Inventors: Lynne Howell, Perrin Baker, Noor Alnabelseya, Natalie Bamford, Dustin Little, Donald Sheppard, Brendan Snarr, Mark Jae Lee
  • Mutated genes for the catalytic protein of oplophorus luciferase and use thereof
    Patent number: 10907134
    Abstract: Luciferases which are different from those known heretofore have been desired. A luciferase mutant comprising an amino acid sequence in which at least one amino acid selected from the group consisting of valine at the position of 44, alanine at the position of 54 and tyrosine at the position of 138 is substituted with other amino acid(s) in the amino acid sequence of SEQ ID NO: 2.
    Type: Grant
    Filed: October 30, 2019
    Date of Patent: February 2, 2021
    Assignee: JNC CORPORATION
    Inventors: Satoshi Inouye, Junichi Sato
  • Oleaginous yeast variant, method for obtaining thereof and use thereof for lipid production
    Patent number: 10889841
    Abstract: The present invention concerns an oleaginous yeast variant of the species Rhodosporidium azoricum characterized by higher biomass yields and intra-cellular lipid accumulation useful for the production of bio-fuels higher, in determined conditions, with respect to the wild type strain of the same species. Furthermore, the invention concerns a method through which said oleaginous yeast variant of the species Rhodosporidium azoricum was obtained. The invention further concerns the lipid production by means of said variant strain of oleaginous yeast of the species Rhodosporidium azoricum.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: January 12, 2021
    Assignee: ENI S.p.A.
    Inventors: Giuliana Franzosi, Daniela Cucchetti, Daniele Bianchi, Silvia Galafassi, Concetta Compagno
  • CRISPR-associated (CAS) protein
    Patent number: 10889808
    Abstract: A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering. CasM proteins are capable of targeting and cleaving single-stranded RNA.
    Type: Grant
    Filed: March 3, 2019
    Date of Patent: January 12, 2021
    Assignee: Locanabio, Inc.
    Inventors: Matthew Merrill Carter, Paul Daniel Donohoue
  • CRISPR-associated (Cas) protein
    Patent number: 10876101
    Abstract: A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering. CasM proteins are capable of targeting and cleaving single-stranded RNA.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: December 29, 2020
    Assignee: Locanabio, Inc.
    Inventors: Matthew Merrill Carter, Paul Daniel Donohoue
  • Biosynthetic gene cluster of carrimycin
    Patent number: 10858659
    Abstract: The present disclosure provides a biosynthetic gene cluster of carrimycin. The biosynthetic gene cluster comprises 44 gene open reading frames (orf), i.e., 5 orfs (orf10-14) encoding polyketide synthase, 9 orfs (orf1, 4-6, 15 and 36-39) related to polyketone synthesis extension unit and modification, 16 orfs (orf9, 16-22, 24, 26, 28, 29, 33-35 and 41) related to glycosyl synthesis, 6 orfs (orf7, 8, 30-32 and 40) related to glycosyl transfer, 2 orfs (orf3 and 25) related to resistance, 4 orfs (orf2, 23, 27 and 42) possibly related to regulation, a tsr resistance marker gene orf (orf43) and a 4?-mycaroseglucoside isovaleryl transferase gene orf (orf44).
    Type: Grant
    Filed: November 24, 2016
    Date of Patent: December 8, 2020
    Assignee: SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO., LTD.
    Inventors: Yiguang Wang, Yang Jiang, Xiaofeng Zhao, Weiqing He, Jianlu Dai
  • Production for recombinant human DNase I
    Patent number: 10858640
    Abstract: Disclosed is a method for production of recombinant human DNase I which is of such high purity as may be directly used as a medical drug. The method includes the steps of; culturing recombinant DNase I-producing mammalian cells, subjecting a culture supernatant to an anion-exchange column chromatography, subjecting to a column chromatography employing as solid phase a material having affinity for phosphate group, subjecting to a cation-exchange column chromatography, and subjecting to a dye affinity column chromatography.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: December 8, 2020
    Assignee: JCR PHARMACEUTICALS CO., LTD.
    Inventors: Yuri Koshimura, Miroslav Matev, Hiroyuki Sonoda
  • Stabilized reverse transcriptase fusion proteins
    Patent number: 10858636
    Abstract: Stabilized reverse transcriptase fusion proteins including a thermostable reverse transcriptase connected to a stabilizer protein are described. Attaching the stabilizer protein to the thermostable reverse transcriptase stabilizes the fusion protein and can aid in its purification, provide increased solubility, allow for longer storage, or allow the fusion protein to be used under more rigorous conditions such as higher temperature. The stabilized reverse transcriptase fusion protein can also include a linker between the stabilizer protein and the thermostable reverse transcriptase. The stabilized reverse transcriptase fusion proteins are suitable for use in nucleic acid amplification methods such as the reverse transcription polymerase chain reaction and other applications involving cDNA synthesis.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: December 8, 2020
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Alan M. Lambowitz, Sabine Mohr, Georg Mohr, Eman Ghanem
  • DNA ligase variants
    Patent number: 10837009
    Abstract: Mutant bacteriophage DNA ligases that have increased tolerance to salt and/or heat is provided. Methods, compositions and kits that employ the same are also provided.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: November 17, 2020
    Assignee: New England Biolabs, Inc.
    Inventors: Jennifer Ong, Gregory Lohman, Aine Quimby, Vladimir Potapov, John M. Pryor
  • Polymerase variants
    Patent number: 10829747
    Abstract: The present disclosure provides variant Pol6 polymerase polypeptides, compositions comprising the Pol6 variant polypeptides, and methods for using the variant Pol6 polypeptides for determining the sequencing of nucleic acids, for example, by nanopore sequencing. The variant Pol6 polymerases possess decreased rates of dissociation of template from the polymerase-template complex, which result in increased processivity relative to the parental Pol6 polypeptides from which they are derived.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: November 10, 2020
    Assignees: Roche Sequencing Solutions, Inc., Roche Molecular Systems, Inc.
    Inventors: Aruna Ayer, Cleoma Arnold, Charles Schwab, Preethi Sarvabhowman, Eileen Thai, Ilya Lederman, Colin McGaw, Evan Amato, Barbara Eckert, Shawn Suko, Mara Boenitz-Dulat, Bigna Woersdoerfer, David Wunderlich